share_log

RBC Capital Reiterates Outperform on Caribou Biosciences, Maintains $14 Price Target

Benzinga ·  Aug 7 11:53  · Ratings

RBC Capital analyst Luca Issi reiterates Caribou Biosciences (NASDAQ:CRBU) with a Outperform and maintains $14 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment